AbbVie Operating Income 2010-2024 | ABBV

AbbVie annual/quarterly operating income history and growth rate from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • AbbVie operating income for the quarter ending March 31, 2024 was $2.798B, a 1.08% increase year-over-year.
  • AbbVie operating income for the twelve months ending March 31, 2024 was $12.787B, a 20.91% decline year-over-year.
  • AbbVie annual operating income for 2023 was $12.757B, a 29.59% decline from 2022.
  • AbbVie annual operating income for 2022 was $18.117B, a 1.08% increase from 2021.
  • AbbVie annual operating income for 2021 was $17.924B, a 57.74% increase from 2020.
AbbVie Annual Operating Income
(Millions of US $)
2023 $12,757
2022 $18,117
2021 $17,924
2020 $11,363
2019 $12,983
2018 $6,383
2017 $9,545
2016 $9,340
2015 $7,537
2014 $3,411
2013 $5,664
2012 $5,817
2011 $3,620
2010 $4,717
2009 $4,932
AbbVie Quarterly Operating Income
(Millions of US $)
2024-03-31 $2,798
2023-12-31 $3,195
2023-09-30 $2,281
2023-06-30 $4,513
2023-03-31 $2,768
2022-12-31 $5,502
2022-09-30 $4,603
2022-06-30 $3,295
2022-03-31 $4,717
2021-12-31 $5,074
2021-09-30 $4,306
2021-06-30 $4,441
2021-03-31 $4,103
2020-12-31 $3,753
2020-09-30 $3,255
2020-06-30 $752
2020-03-31 $3,603
2019-12-31 $3,956
2019-09-30 $2,617
2019-06-30 $3,400
2019-03-31 $3,010
2018-12-31 $-2,441
2018-09-30 $3,159
2018-06-30 $2,762
2018-03-31 $2,903
2017-12-31 $1,782
2017-09-30 $2,694
2017-06-30 $2,662
2017-03-31 $2,407
2016-12-31 $2,314
2016-09-30 $2,361
2016-06-30 $2,387
2016-03-31 $2,278
2015-12-31 $2,113
2015-09-30 $1,885
2015-06-30 $1,852
2015-03-31 $1,687
2014-12-31 $-415
2014-09-30 $960
2014-06-30 $1,515
2014-03-31 $1,351
2013-12-31 $1,535
2013-09-30 $1,371
2013-06-30 $1,453
2013-03-31 $1,305
2012-12-31 $1,821
2012-09-30 $1,596
2012-06-30 $1,422
2012-03-31 $978
2011-12-31 $-5,887
2011-09-30 $4,409
2011-06-30 $4,274
2011-03-31 $824
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $293.876B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01